Developer docs
API playgroundTry for free, no card

Search company profiles

MetaShape Pharma

Full company profile

uuid00kd8d7

Namestring
MetaShape Pharma
Legal namestring
MetaShape Pharma AG
Company typeenum
Private
Founded yearint
2023
Descriptiontext

MetaShape Pharma AG is a Switzerland-domiciled preclinical biopharmaceutical company founded in 2023 and headquartered in Riehen (Basel), developing first-in-class metabolic therapies for obesity and cardiometabolic disorders. Its lead and only product candidate, MS 001 (ulodesine hemiglutarate), is an oral small-molecule inhibitor of purine nucleoside phosphorylase (PNP) designed to act as a metabolic amplifier for GLP-1 receptor agonists such as semaglutide and tirzepatide. Mechanistically, MS 001 inhibits PNP to preserve NAD+ precursors, elevating inosine and NAD+ levels in white adipose tissue and activating fat-selective energy-expenditure pathways — including futile calcium cycling and glucagon signaling — intended to drive selective fat loss, preserve lean muscle mass, and reduce weight regain after GLP-1 therapy is discontinued.

The underlying technology is a patent-pending novel salt form of ulodesine (a compound previously evaluated in over 500 human subjects with a generally safe and well-tolerated profile), with composition-of-matter and method-of-use patent applications expected to provide protection into the early 2040s. Preclinical data presented at ADA 2026 showed that low-dose MS 001 combined with semaglutide produced greater weight loss, preserved muscle, and reduced weight regain versus semaglutide alone in diet-induced obese mice. The company's scientific advisory group includes Professor Shingo Kajimura (Harvard Medical School/HHMI), an authority on human bioenergetics and futile calcium cycling, alongside collaborators at UCLA, Washington University, Mayo Clinic, and the National University of Singapore.

MetaShape has no commercial product, no disclosed revenue, and a headcount of 1–10. Its business model contemplates advancing MS 001 through clinical proof of concept — with initial efficacy data targeted for 2029 — either independently or via licensing/partnership with larger pharmaceutical companies, with revenue intended to come from upfront licensing fees, milestone payments, and royalties. The company is currently preparing a US$10 million Series A financing to fund this path and is actively presenting at scientific and investor conferences (ADA Scientific Sessions, Swiss Biotech Day, Longevity Investors Conference) to build visibility with potential pharma partners and investors.

Short descriptiontext

MetaShape Pharma AG is a Switzerland-based preclinical biotech developing MS 001, an oral PNP inhibitor designed to amplify GLP-1 obesity therapy by increasing fat-specific energy expenditure while preserving muscle mass. The company is pre-revenue, preparing a US$10M Series A, and targets eventual out-licensing to pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRiehen, Switzerland
HQ citystring
Riehen
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
metabolic disease therapeutics, obesity drug development, GLP-1 co-therapy, small molecule inhibitors, preclinical biotechnology
Industry2 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Obesity Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Licensing
TypeLicensing Royalties
Description

MetaShape Pharma is a preclinical-stage biopharmaceutical company developing MS 001 for obesity and cardiometabolic disorders. The company plans to advance MS 001 through clinical development via a planned $10 million Series A financing, with the intent to either independently develop through clinical proof-of-concept or partner/license with larger pharmaceutical companies. Revenue would be generated through licensing deals, milestone payments, and eventual product sales if approved.

metashapepharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MetaShape Pharma develops MS 001 (ulodesine hemiglutarate), a first-in-class oral small-molecule inhibitor of purine nucleoside phosphorylase (PNP) intended as a metabolic amplifier for GLP-1 receptor agonists in the treatment of obesity and cardiometabolic disorders. The compound elevates NAD+ and inosine levels to drive fat-selective energy expenditure via futile calcium cycling, preserving muscle mass and reducing weight regain. The company is preclinical-stage and intends to license or partner MS 001 with larger pharmaceutical companies for late-stage development and commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to 40% of weight lost with GLP-1 receptor agonists consists of lean muscle mass (Linge et al., 2024)
+3 more records
Product overview1 text field

MetaShape Pharma is developing MS 001 (ulodesine hemiglutarate), a first-in-class oral small-molecule drug and metabolic amplifier designed to work alongside GLP-1 receptor agonists (such as semaglutide and tirzepatide). The product reprograms fat metabolism to enhance fat-selective weight loss, preserve muscle mass, and reduce weight regain following GLP-1 discontinuation, addressing key limitations of current GLP-1 monotherapies. The company is a preclinical-stage biopharma focused on obesity and cardiometabolic disorders, with MS 001 as its lead and only product candidate in pre-IND development.

Product and service1 record
1MS 001 (ulodesine hemiglutarate)
CategoryObesity therapeutics / cardiometabolic drug candidate
Description

First-in-class oral small-molecule inhibitor of purine nucleoside phosphorylase (PNP) designed as a metabolic amplifier for GLP-1 receptor agonists. Increases fat-specific energy expenditure via futile calcium cycling and glucagon-signaling pathways in white adipose tissue, preserving muscle mass and reducing weight regain in obesity and cardiometabolic disease treatment. Patent-pending novel salt form of ulodesine.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Professor Shingo Kajimura (Harvard Medical School/BIDMC)
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2026-01-05
Description

MetaShape Pharma entered into a consulting agreement with Professor Shingo Kajimura, a world-leading authority in human bioenergetics and adipose tissue biology, to advise on the development strategy of MS 001. Professor Kajimura is Investigator at Howard Hughes Medical Institute (HHMI), Professor of Medicine at Harvard Medical School, and Faculty Member at Beth Israel Deaconess Medical Center (BIDMC). He will guide the development of MS 001 as a first-in-class oral PNP inhibitor for obesity treatment.

einpresswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
TypeBroad incumbent
Description

Global pharmaceutical leader and incumbent in the GLP-1 obesity market (Zepbound/Mounjaro); sets the standard MetaShape's MS 001 is designed to complement and is the most likely large-pharma partner or acquirer.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics targeting the TGF-β superfamily for hematological and cardiometabolic disorders, including obesity-related indications; comparable stage, size, and disease focus to MetaShape.

TypeDirect peer
Description

Clinical-stage biotech developing controlled metabolic accelerators (e.g., HU6) for obesity and cardiometabolic disease via increased fat-specific energy expenditure—the same mechanism thesis as MetaShape's MS 001, making it the most directly comparable peer.

TypeEmerging player
Description

Clinical-stage biotech developing therapeutics targeting the biology of aging and metabolic disease, including obesity-relevant pathways—overlaps with MetaShape's NAD+ / metabolic amplifier thesis and targets similar patient populations.

TypeDirect peer
Description

Clinical-stage biotech developing oral small molecules for obesity (e.g., TERN-601, a GLP-1R agonist), competing in the same oral obesity drug space that MetaShape targets for cardiometabolic indications.

TypeDirect peer
Description

Public clinical-stage biotech developing oral small-molecule GLP-1R agonists (e.g., aleniglipron) for obesity and type 2 diabetes—same disease space, oral small-molecule approach, and cardiometabolic focus as MetaShape.

TypeDirect peer
Description

Clinical-stage biotech developing peptide-based therapeutics for obesity and liver diseases, including pemvidutide for obesity—a peer pursuing a complementary mechanism (GLP-1/glucagon dual agonist) in the same metabolic disease category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MetaShape Pharma

Obesity Therapeuticsmetashapepharma.com

MetaShape Pharma AG is a Switzerland-based preclinical biotech developing MS 001, an oral PNP inhibitor designed to amplify GLP-1 obesity therapy by increasing fat-specific energy expenditure while preserving muscle mass. The company is pre-revenue, preparing a US$10M Series A, and targets eventual out-licensing to pharmaceutical partners.

What MetaShape Pharma does

MetaShape Pharma AG is a Switzerland-domiciled preclinical biopharmaceutical company founded in 2023 and headquartered in Riehen (Basel), developing first-in-class metabolic therapies for obesity and cardiometabolic disorders. Its lead and only product candidate, MS 001 (ulodesine hemiglutarate), is an oral small-molecule inhibitor of purine nucleoside phosphorylase (PNP) designed to act as a metabolic amplifier for GLP-1 receptor agonists such as semaglutide and tirzepatide. Mechanistically, MS 001 inhibits PNP to preserve NAD+ precursors, elevating inosine and NAD+ levels in white adipose tissue and activating fat-selective energy-expenditure pathways — including futile calcium cycling and glucagon signaling — intended to drive selective fat loss, preserve lean muscle mass, and reduce weight regain after GLP-1 therapy is discontinued.

The underlying technology is a patent-pending novel salt form of ulodesine (a compound previously evaluated in over 500 human subjects with a generally safe and well-tolerated profile), with composition-of-matter and method-of-use patent applications expected to provide protection into the early 2040s. Preclinical data presented at ADA 2026 showed that low-dose MS 001 combined with semaglutide produced greater weight loss, preserved muscle, and reduced weight regain versus semaglutide alone in diet-induced obese mice. The company's scientific advisory group includes Professor Shingo Kajimura (Harvard Medical School/HHMI), an authority on human bioenergetics and futile calcium cycling, alongside collaborators at UCLA, Washington University, Mayo Clinic, and the National University of Singapore.

MetaShape has no commercial product, no disclosed revenue, and a headcount of 1–10. Its business model contemplates advancing MS 001 through clinical proof of concept — with initial efficacy data targeted for 2029 — either independently or via licensing/partnership with larger pharmaceutical companies, with revenue intended to come from upfront licensing fees, milestone payments, and royalties. The company is currently preparing a US$10 million Series A financing to fund this path and is actively presenting at scientific and investor conferences (ADA Scientific Sessions, Swiss Biotech Day, Longevity Investors Conference) to build visibility with potential pharma partners and investors.

MetaShape Pharma firmographics

Firmographics
Name
MetaShape Pharma
Legal name
MetaShape Pharma AG
Website
https://metashapepharma.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
MetaShape Pharma AG is a Switzerland-based preclinical biotech developing MS 001, an oral PNP inhibitor designed to amplify GLP-1 obesity therapy by increasing fat-specific energy expenditure while preserving muscle mass. The company is pre-revenue, preparing a US$10M Series A, and targets eventual out-licensing to pharmaceutical partners.
Ownership category
akta.pro rank

MetaShape Pharma industry classification

Industry
Product category
Obesity Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Metabolic disease therapeutics
  • Obesity drug development
  • GLP-1 co-therapy
  • Small molecule inhibitors
  • Preclinical biotechnology

Where MetaShape Pharma is headquartered

Location

Headquarters

HQ city
Riehen
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

MetaShape Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Drug Development and Licensing: MetaShape Pharma is a preclinical-stage biopharmaceutical company developing MS 001 for obesity and cardiometabolic disorders. The company plans to advance MS 001 through clinical development via a planned $10 million Series A financing, with the intent to either independently develop through clinical proof-of-concept or partner/license with larger pharmaceutical companies. Revenue would be generated through licensing deals, milestone payments, and eventual product sales if approved.

Go-to-market motion1 record

Marketing channels4 records

MetaShape Pharma product offering

Product offering

Core offering

MetaShape Pharma develops MS 001 (ulodesine hemiglutarate), a first-in-class oral small-molecule inhibitor of purine nucleoside phosphorylase (PNP) intended as a metabolic amplifier for GLP-1 receptor agonists in the treatment of obesity and cardiometabolic disorders. The compound elevates NAD+ and inosine levels to drive fat-selective energy expenditure via futile calcium cycling, preserving muscle mass and reducing weight regain. The company is preclinical-stage and intends to license or partner MS 001 with larger pharmaceutical companies for late-stage development and commercialization.

Product overview

MetaShape Pharma is developing MS 001 (ulodesine hemiglutarate), a first-in-class oral small-molecule drug and metabolic amplifier designed to work alongside GLP-1 receptor agonists (such as semaglutide and tirzepatide). The product reprograms fat metabolism to enhance fat-selective weight loss, preserve muscle mass, and reduce weight regain following GLP-1 discontinuation, addressing key limitations of current GLP-1 monotherapies. The company is a preclinical-stage biopharma focused on obesity and cardiometabolic disorders, with MS 001 as its lead and only product candidate in pre-IND development.

Differentiator

Problem solved

Functional benefit

Products and services

  • MS 001 (ulodesine hemiglutarate) First-in-class oral small-molecule inhibitor of purine nucleoside phosphorylase (PNP) designed as a metabolic amplifier for GLP-1 receptor agonists. Increases fat-specific energy expenditure via futile calcium cycling and glucagon-signaling pathways in white adipose tissue, preserving muscle mass and reducing weight regain in obesity and cardiometabolic disease treatment. Patent-pending novel salt form of ulodesine.

Quantifiable outcome

  • Up to 40% of weight lost with GLP-1 receptor agonists consists of lean muscle mass (Linge et al., 2024)
  • +3 more outcomes

Companies that use MetaShape Pharma

Customer profile

Segments1 record

Ideal customer profiles3 records

MetaShape Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

MetaShape Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Professor Shingo Kajimura (Harvard Medical School/BIDMC)keyStrategic or Co-development Partner · 5 January 2026MetaShape Pharma entered into a consulting agreement with Professor Shingo Kajimura, a world-leading authority in human bioenergetics and adipose tissue biology, to advise on the development strategy of MS 001. Professor Kajimura is Investigator at Howard Hughes Medical Institute (HHMI), Professor of Medicine at Harvard Medical School, and Faculty Member at Beth Israel Deaconess Medical Center (BIDMC). He will guide the development of MS 001 as a first-in-class oral PNP inhibitor for obesity treatment.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

MetaShape Pharma competitors and assessment

Company assessment

Broad incumbents

  • Novo Nordisk:
  • Eli Lilly: Global pharmaceutical leader and incumbent in the GLP-1 obesity market (Zepbound/Mounjaro); sets the standard MetaShape's MS 001 is designed to complement and is the most likely large-pharma partner or acquirer.

Direct peers

  • Keros Therapeutics: Clinical-stage biotech developing therapeutics targeting the TGF-β superfamily for hematological and cardiometabolic disorders, including obesity-related indications; comparable stage, size, and disease focus to MetaShape.
  • Rivus Pharmaceuticals: Clinical-stage biotech developing controlled metabolic accelerators (e.g., HU6) for obesity and cardiometabolic disease via increased fat-specific energy expenditure—the same mechanism thesis as MetaShape's MS 001, making it the most directly comparable peer.
  • Terns Pharmaceuticals: Clinical-stage biotech developing oral small molecules for obesity (e.g., TERN-601, a GLP-1R agonist), competing in the same oral obesity drug space that MetaShape targets for cardiometabolic indications.
  • Structure Therapeutics: Public clinical-stage biotech developing oral small-molecule GLP-1R agonists (e.g., aleniglipron) for obesity and type 2 diabetes—same disease space, oral small-molecule approach, and cardiometabolic focus as MetaShape.
  • Altimmune: Clinical-stage biotech developing peptide-based therapeutics for obesity and liver diseases, including pemvidutide for obesity—a peer pursuing a complementary mechanism (GLP-1/glucagon dual agonist) in the same metabolic disease category.

Emerging players

  • BioAge Labs: Clinical-stage biotech developing therapeutics targeting the biology of aging and metabolic disease, including obesity-relevant pathways—overlaps with MetaShape's NAD+ / metabolic amplifier thesis and targets similar patient populations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

MetaShape Pharma social profiles

Digital presence

MetaShape Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MetaShape Pharma leadership team

Management profile

Number of profiles

Profiles12 records

MetaShape Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MetaShape Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MetaShape Pharma

What does MetaShape Pharma do?

MetaShape Pharma develops MS 001 (ulodesine hemiglutarate), a first-in-class oral small-molecule inhibitor of purine nucleoside phosphorylase (PNP) intended as a metabolic amplifier for GLP-1 receptor agonists in the treatment of obesity and cardiometabolic disorders. The compound elevates NAD+ and inosine levels to drive fat-selective energy expenditure via futile calcium cycling, preserving muscle mass and reducing weight regain. The company is preclinical-stage and intends to license or partner MS 001 with larger pharmaceutical companies for late-stage development and commercialization.

Is MetaShape Pharma a public or private company?

MetaShape Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was MetaShape Pharma founded?

MetaShape Pharma was founded in 2023. It employs 1 to 10 people.

Where is MetaShape Pharma based?

MetaShape Pharma is headquartered in Riehen, Switzerland, in the Europe region.

How does MetaShape Pharma make money?

One revenue line is on record: drug Development and Licensing.

Who are MetaShape Pharma's main competitors?

Broad incumbents on record are Novo Nordisk and Eli Lilly. Direct peers are Keros Therapeutics, Rivus Pharmaceuticals, Terns Pharmaceuticals, Structure Therapeutics and Altimmune. BioAge Labs is listed as an emerging player.

Does MetaShape Pharma have an API?

No public API is recorded for MetaShape Pharma.

What industry is MetaShape Pharma in?

MetaShape Pharma's product category is Obesity Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireMetaShape Pharma to Showcase New Data and Strategic Updates at MedInvest and RESI Life Sciences Investor ConferencesMetaShape Pharma will present new preclinical data and strategic updates for MS 001 at MedInvest and RESI investor conferences in September. The oral co-therapy aims to enhance GLP-1 weight loss by increasing energy expenditure while preserving muscle. The company is preparing a $20 million Series A financing, with initial efficacy data expected in 2029.Longevity.TechnologyMetaShape targets GLP-1’s biggest weaknessesMetaShape Pharma presented preclinical data at the 2026 American Diabetes Association Scientific Sessions showing that its lead candidate MS 001, when combined with semaglutide, achieved greater weight loss, increased muscle weight and endurance, and reduced weight regain after treatment discontinuation compared to semaglutide alone in animal models. The therapy appeared to work by increasing energy expenditure and fat metabolism rather than further reducing food intake, addressing key limitations of current GLP-1 treatments. The Swiss biotech is preparing a $10 million Series A financing round to advance MS 001 toward clinical development, with initial efficacy data anticipated in 2029.EIN PresswireMetaShape Pharma Presents New Data on MS 001 in Combination with GLP-1 Receptor Agonists at ADA 2026 Scientific SessionsMetaShape Pharma presented preclinical data on MS 001 combined with semaglutide and tirzepatide at ADA 2026, showing deeper fat-selective weight loss, muscle preservation, and reduced weight regain. The data suggest MS 001 enhances GLP-1 efficacy by increasing adipose thermogenesis, with a planned Series A financing of $10 million.Longevity.TechnologyMetashape Pharma to present new data on GLP-1 combination, muscle healthMetashape Pharma will present preclinical data on MS 001 combined with semaglutide at the American Diabetes Association 2026 Scientific Sessions in New Orleans. The abstract, under embargo until 5 June, reports increased thermogenesis, selective fat loss, and muscle preservation in diet-induced obese mice. The company describes MS 001 as an oral purine nucleoside phosphorylase inhibitor in pre-IND development.EIN PresswireMetaShape Pharma Announces Presentations at the American Diabetes Association’s 2026 Scientific SessionsMetaShape Pharma announced new preclinical data on MS 001 with semaglutide will be presented at the ADA 2026 Scientific Sessions in New Orleans. The abstract, selected for both Late Breaking Poster and ePoster Theater, remains under embargo until June 5. The data shows increased thermogenesis and selective fat loss while preserving muscle mass in mice.EIN PresswireMetaShape Pharma Appoints World-Leading Bioenergetics Expert, Professor Shingo Kajimura, as Scientific AdvisorMetaShape Pharma AG announced the appointment of Professor Shingo Kajimura, a leading expert in human bioenergetics and adipose tissue biology at Harvard Medical School, as a Scientific Advisor under a consulting agreement dated January 5, 2026. Professor Kajimura will guide the development of MS 001, a first-in-class oral PNP inhibitor in pre-IND development for obesity treatment that works synergistically with GLP-1 receptor agonists, promoting selective fat loss while preserving muscle mass. The appointment underscores MetaShape's strategy to advance metabolic therapies addressing limitations of current GLP-1-based treatments for obesity and cardiometabolic disease.NadBiotech Startup Aims to Harness New NAD+-Related Drug Against AgingThe longevity biotech company, MetaShape, is developing a new compound, MS 001, designed to restore cellular nicotinamide adenine dinucleotide (NAD+) to combat age-related conditions like high cholesterol, cognitive decline, and neurodegenerative diseases. The company plans to conduct its first human trial within a year and aims for regulatory approval of MS 001 within three years, marking a significant step in the field of longevity therapeutics. MetaShape was founded in 2023 and builds its approach on previously designed technologies and recent findings on NAD+ precursor degradation.